Condition: Chondral Defect · Articular Cartilage Defect · Sponsor: Vericel Corporation
The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus.
This description comes directly from the study's public registry record.
Vericel Clinical Affairs · 978-347-2876 · clinicalhotline@vcel.com
Always discuss trial participation with your own doctor first.
| UC Davis Foot and Ankle Clinic | Sacramento, California, United States | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Elevate Clinical Research Wichita | Wichita, Kansas, United States | Recruiting |
| Duke Orthopaedic Surgery | Durham, North Carolina, United States | Recruiting |
| Elevate Clinical Research | Houston, Texas, United States | Recruiting |
| Rodaro, LLC | San Antonio, Texas, United States | Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06915233